Major ABO incompatible BM transplantation carries a risk of acute haemolysis. Red cell depletion reduces this risk but not all incompatible RBC (iRBCs) are removed and in children the residual volume can be significant relative to body weight. We sought to determine the volume of iRBCs that can be safely given to children. All patients receiving fresh BM from a donor with a major ABO blood group mismatch between January 2000 and July 2013 at the Hospital for Sick Children, Toronto, were included. Seventy-eight patients were identified. The median volume of iRBCs transfused was 1.6 mL/kg (range 0.1-10.6 mL/kg). Thirty-five patients had minor haemolytic events and five patients had clinically significant adverse events. Two patients, who received 3.66 and 3.9 mL iRBCs/kg, developed renal impairment and in one case hypoxia and hyperbilirubinaemia. One patient had mild hypotension that resolved with i.v. fluid. Two patients developed hypotension secondary to sepsis and unrelated to BM infusion. Although signs of haemolysis occur, with appropriate hydration and monitoring of renal function, clinically significant adverse events related to the infusion of ABO incompatible BM are rare, and, in this study, were only seen in patients receiving 43 mL/kg of iRBCs per kg.
INTRODUCTION
ABO incompatibility between donor and recipient is not a contraindication to allogeneic haematopoietic SCT (HSCT). However, a number of immunohaematological issues must be carefully considered and appropriately managed. 1 Major ABO mismatch is characterised by preformed recipient isoagglutinins to donor red cell antigens, and minor ABO mismatch occurs when the graft contains isoagglutinins directed against recipient red cells. Bidirectional mismatch occurs when both situations are present. 1 The risks of major ABO incompatibility include acute haemolysis at the time of graft infusion, delayed engraftment and pure red cell aplasia. 2 The literature suggests that 20-30 mL of incompatible RBCs (iRBCs) can be safely infused into an adult 2 and this has been extrapolated to 0.2-0.4 mL/kg, but there is no evidence about safe volumes in children. In the case of major ABO incompatibility, most centres will red cell deplete donor BM using centrifugation or sedimentation techniques. 2 Even with the best available technology it is not possible to remove all iRBCs and in small children this can result in a volume of red cells per kilogram of wt that is significantly higher than would routinely be transfused into an adult. In our experience we are rarely able to red cell deplete BM such that 40.4 mL/kg of iRBCs remain, without significantly reducing the total nucleated cell dose and thus jeopardising engraftment. Therefore, we sought to determine what volume of iRBCs can safely be given to children in the context of allogeneic HSCT using fresh BM.
SUBJECTS AND METHODS
Data were collected from a large paediatric HSCT centre at The Hospital for Sick Children in Toronto.
All patients receiving BM from a donor with a major ABO blood group mismatch between 1 January 2000 and 1 August 2013 were identified from stem cell laboratory processing records. Major ABO incompatibility was defined as a blood group O recipient receiving BM from a blood group A or B donor. For the purposes of this study, major ABO incompatibility included bidirectional incompatibility which was defined as a blood group A recipient receiving BM from a blood group B donor or vice versa. Patients receiving PBSCs and umbilical cord blood were excluded. A retrospective chart review was conducted. Minor haemolytic events were defined as: an increase in creatinine of 25-50% from baseline within 24 h of BM infusion, an increase in unconjugated bilirubin above the upper limit of normal (17 mmol/L) within 24 h of BM infusion, clinically apparent haemoglobinuria or fever. Clinically significant adverse events were defined as: an increase in creatinine of 450% from baseline within 24 h of BM infusion or hypotension requiring fluid resuscitation of 10 mL/kg or more of i.v. fluid. The study was approved by the local research ethics board.
RESULTS

Patient characteristics
A total of 83 patients were identified of whom adequate data for full analysis was available for 78. Patient characteristics are detailed in Table 1 .
Standard supportive care
Recipient anti-A and anti-B titres were not measured. No attempt was made to reduce recipient isoagglutinins using plasma exchange or donor type plasma prior to BM infusion. Although some HSCT centres routinely measure recipient anti-A and anti-B titres and use this value to help determine the need for red cell depletion, practice at our centre has been not to measure Ab levels but to red cell deplete all fresh BM from major ABO incompatible donors. The BM was red cell depleted using pentaspan sedimentation in 74 of the 78 cases. In four cases, the total nucleated cell dose was deemed to be too low to risk any cell loss during the process of red cell depletion. All patients received diphenhydramine and acetaminophen prior to BM infusion. In addition, some patients received hydrocortisone and/or meperidine. Hyperhydration (125 mL/m 2 /h) was given for 2 h before and at least 4 h after BM infusion. In cases of visible haemoglobinuria, hyperhydration was continued until the urine colour normalised. The duration of the BM infusion varied depending on the volume of marrow to be infused, the wt of the child and the volume of iRBCs. The median duration from the start of the of infusion until completion of the final bag, even if a deliberate gap was left between bags, was 4.5 h (range 0.5-24 h) with a median rate of 0.33 mL of iRBCs/kg/h, (range 0.04-3.16 mL/kg/h).
Volumes of incompatible red cells and reactions
The median volume of iRBCs was 1.6 mL/kg (range 0.11-10.61 mL/kg). In the four patients where red cell depletion was not carried out, the median volume of iRBCs was 3.55 mL/kg (range 2.1-10.5 mL/kg). In the remaining 74 patients, the median volume of iRBCs was 1.6 mL/kg (range 0.11-6.54 mL/kg). Only two patients received o0.4 mL/kg. A 7 kg infant received 0.11 mL/kg of iRBCs and a 48 kg child received 0.37 mL/kg. Neither patient had any signs of haemolysis.
Forty-three patients (55%) had no minor haemolytic or clinically significant adverse event. Thirty patients (38%) had a minor haemolytic event and five patients (6%) had a clinically significant adverse event (Figure 1 ). Transient increases in unconjugated bilirubin above the upper limit of normal were seen in 24 patients (31%), an increase in creatinine of 25-50% from baseline was seen in 7 patients (9%), haemoglobinuria was detected clinically in 12 patients (15%) and 6 patients (8%) had a fever during the infusion. Two patients (3%) became hypotensive requiring fluid resuscitation and in one case inotropic support was also required. Three patients (4%) had an increase in creatinine by 450% but none required haemofiltration or dialysis.
No patient developed haemolytic anaemia as a late complication of HSCT.
Clinically significant adverse events The five patients who had a clinically significant adverse event were studied in more detail to establish if their symptoms were attributable to the infusion of ABO incompatible BM. In all cases, the BM had undergone red cell depletion.
Patient 1, a 4-year-old boy, developed septic shock secondary to streptococcus viridans bacteraemia on the day of BM infusion. His clinical condition was deteriorating rapidly and he required inotropic support and non-invasive ventilation. Despite worsening respiratory failure, the decision to proceed with BM infusion was made. He received 2.22 mL/kg of iRBCs. His respiratory decline continued and 2 h into the BM infusion he required intubation and invasive ventilation. His creatinine increased over the next 24 h by 150%, in the context of sepsis induced multi-organ failure. He died 36 h after BM infusion of respiratory and circulatory failure due to uncontrolled infection.
Patient 2, a 13-year-old boy, developed hypoxia and haemoglobinuria without hypotension during BM infusion. He received 3.9 mL/kg of iRBCs cells over 130 min (1.75 mL of iRBCs/kg/h). The hypoxia resolved within 12 h following treatment with antibiotics and hydrocortisone. There was a significant rise in unconjugated bilirubin (9-65 mmol/L) and creatinine (35-76 mmol/L), however, his urine output remained adequate at all times. Hyperhydration was continued for 48 h and the creatinine improved to a plateau of 40-50 mmol/L. Patient 3, a 10-month-old boy, had a 62% increase in creatinine following the BM infusion (13-21 mmol/L) but no increase in unconjugated bilirubin. Urine output remained adequate at all times and creatinine returned to baseline within 48 h. He received 3.66 mL/kg of iRBCs over 300 min.
Patient 4, a 5-year-old boy developed fever and hypotension during the BM infusion. He received a total of 0.68 mL/kg of iRBCs over 235 min. The hypotension did not respond to broad spectrum antibiotics and fluid resuscitation. Inotropic support was required for o 24 h. No positive microbiology was identified and the patient made a full recovery. There was no significant increase in creatinine or bilirubin to suggest acute haemolysis and it was felt most likely that the symptoms were attributable to infection.
Patient 5, a 15-year-old girl, received a total of 1.43 mL/kg of iRBCs over 330 min. During the infusion, her blood pressure Total allogeneic HSCT n = 570
Major ABO incompatible, fresh BM n = 83
Non-Evaluable n = 5
Evaluable n = 78
Minor haemolytic reactions n = 30
Clinically significant adverse events n = 5
Related to infusion of ABO incompatible BM n = 3
Related to infection n = 2 Figure 1 . Number of events.
Paediatric ABO incompatible BMT K Patrick et al dropped from 125/67 to 97/42 mm Hg. The hypotension resolved following a 10 mL/kg bolus of 0.9% sodium chloride. The BM infusion was continued without further haemodynamic instability. There was no significant increase in creatinine or unconjugated bilirubin.
Risk of reactions according to volume of incompatible red cells
There was no significant difference in the mean volume of iRBCs given to those patients who had any minor haemolytic or clinically significant adverse event compared with those who did not (1.9 mL/kg, n = 35 vs 2.1 mL/kg, n = 43, P = 0.5). The mean duration of the BM infusion was similar between the two groups (339 min vs 299 min). Thirteen patients received 43 mL/kg of iRBCs. This group received a median of 3.97 mL of iRBCs/kg (range 3.09-10.61 mL/kg, mean 4.56 mL/kg) over a median of 263 min (range 130-525 min, mean 295 min). Five patients had a transient rise in bilirubin and two patients (patients 2 and 3 described above) had an increase in creatinine of 450%.
Four patients received BM without RBC depletion due to a low total nucleated cell dose. These patients received a mean of 4.95 mL/kg of iRBCs (range 2.13-10.53 mL/kg). One patient had no signs of haemolysis. The other three patients had a rise in unconjugated bilirubin and in one case haemoglobinuria. None of the four patients had a clinically significant adverse event.
Sixty-five patients received o3 mL/kg of iRBCs. The group received a median of 1.46 mL/kg of iRBCs (range 0.11-2.99 mL/kg, mean 1.51 mL/kg) over a median of 270 min (range 30-1440, mean 321). Nineteen patients had a transient increase in bilirubin, seven patients had an increase in creatinine of 25-50%, one patient (patient 1) had a creatinine increase of 450% but this was in the context of severe infection and two patients (patients 4 and 5) developed hypotension, although in both cases it is not clear if the BM infusion was the cause.
Although minor haemolytic reactions occurred in both groups, the only significant events definitely attributable to the infusion of incompatible BM occurred in patients who received 43 mL/kg (3.66 and 3.9 mL/kg) of iRBCs.
Patient outcomes
Seventy-three patients achieved neutrophil engraftment (defined as a neutrophil count 40.5 × 10 9 /L for 3 consecutive days) at a median of day +23. There were no cases of pure red cell aplasia. With a median follow-up of 8.5 years, 51 patients (65%) were still alive. Of the twenty-seven deaths, 9 were due to disease relapse and 18 were due to non-relapse mortality, although none were attributable to the infusion of ABO incompatible BM. One patient (patient 1) died on day +1 from uncontrolled streptococcal sepsis unrelated to the BM infusion. Two patients died in other hospitals and the cause of death was not available.
DISCUSSION
We describe a large cohort of children who received HSCT using fresh BM from major ABO incompatible donors. Although biochemical signs of haemolysis were common, we have demonstrated that with careful hydration, close attention to urine output and monitoring of creatinine and bilirubin significantly more than the previously recommended 0.4 mL/kg of iRBCs can safely be given to children. Only 2 of the 78 patients had clinically significant reactions attributable to the transfusion of iRBCs and these patients received 3.66 and 3.9 mL/kg. In addition, the patient who received 3.9 mL/kg was given the cells at a rate of 1.75 mL iRBCs/kg/h, much faster than the median of 0.33 mL iRBCs/kg/h, and it is possible that had the infusion been given more slowly the adverse consequences could have been minimised. No patient developed haemolytic anaemia as a late complication of ABO incompatible HSCT.
